GW6471, solid, >=98% (HPLC), off-white to light yellow

Application

GW6471 has been used:to investigate the role of peroxisome proliferator-activated receptors (PPARs) alpha in perfluorooctanoic acid (PFOA) induced developmental cardiotoxicityto abolish the protection of bezafibrate (BZA) against hypertrophyto block the enhanced activity of the hepatitis B virus (HBV) core promoter

Biochem/physiol Actions

GW6471 is a PPARα antagonist, which completely inhibits GW409544-induced activation of PPARα with an IC₅₀ = 0.24 µM. GW6471 induces a PPARα conformation that interacts efficiently with co-repressors.

Features and Benefits

This compound is featured on the Nuclear Receptors (PPARs) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

This compound is a featured product for Gene Regulation research. Click here to discover more featured Gene Regulation products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

General description

GW6471 prevents apoptosis and cell cycle arrest at G₀/G₁ in renal cell carcinoma. It reduces enhanced fatty acid oxidation and oxidative phosphorylation associated with glycolysis inhibition.

Packaging

5 mg in glass bottle